Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop.

@article{Huse2014WhereAW,
  title={Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop.},
  author={Jason T Huse and Max Wallace and Kenneth D. Aldape and Mitchel S. Berger and C Bettegowda and Daniel J. Brat and Daniel P Cahill and Timothy C. Cloughesy and Daphne Adele Haas-Kogan and Marco A. Marra and C Ryan Miller and Sarah J. Nelson and Sofie R. Salama and Riccardo Soffietti and Patrick Yung Chih Wen and Stephen Yip and K Lawrence Yen and Joseph F. Costello and Susan Chang},
  journal={Neuro-oncology},
  year={2014},
  volume={16 2},
  pages={173-8}
}
Diffuse gliomas consist of both low- and high-grade varieties, each with distinct morphological and biological features. The often extended periods of relative indolence exhibited by low-grade gliomas (LGG; WHO grade II) differ sharply from the aggressive, rapidly fatal clinical course of primary glioblastoma (GBM; WHO grade IV). Nevertheless, until recently, the molecular foundations underlying this stark biological contrast between glioma variants remained largely unknown. The discoveries of… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

The Role of ATRX in Glioma Biology

View 4 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2012
View 4 Excerpts
Highly Influenced

Glioblastoma : molecularanalysis and clinical implications

JT Huse, LM DeAngelis
Annu Rev Med • 2013

HollandE, DeAngelis LM.Glioblastoma: molecularanalysis and clinical implications

JT Huse
Annu Rev Med • 2013
View 1 Excerpt

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.

Proceedings of the National Academy of Sciences of the United States of America • 2013
View 1 Excerpt

Chemotherapy in low-grade gliomas.

Current opinion in oncology • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…